Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG-fluorescent Imaging for Sentinel Lymph Node Mapping in Breast Cancer
NCT05859971Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of indocyanine green in breast cancer, sponsored by University of Wisconsin–Madison. Primary endpoints: Concordance Between Detection of Sentinel Lymph Nodes by ICG Versus Technetium-99, at the Lymph Node Level and Concordance Between Detection of Sentinel Lymph Nodes by ICG Versus Technetium-99, at the Patient Level. Started Apr 2023; status: completed.
02
Drugs
indocyanine green
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05859971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05859971.